In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.

Published Date: 03 Jun 2024

According to experts, the benefit-risk profile may alter the way CML is treated.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.

2.

CAR-T cell therapy for cancer causes 'brain fog,' study shows

3.

Mutation Correlates with a Higher Prostate Cancer Mortality Risk.

4.

Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

5.

ALK-positive lung cancer trial results show unprecedented progression-free survival.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot